What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary areas of investigation include Internal medicine, Lung cancer, Oncology, Surgery and Cancer research. In most of his Internal medicine studies, his work intersects topics such as Gastroenterology. His Lung cancer study incorporates themes from Cancer, Chemotherapy regimen, Adenocarcinoma and Carcinoma.
His Oncology study combines topics in areas such as KRAS, Dabrafenib and Docetaxel. His Surgery research is multidisciplinary, incorporating perspectives in Clinical trial, Adverse effect, Targeted therapy and Nivolumab, Immunotherapy. His Cancer research research integrates issues from Carcinogenesis, Downregulation and upregulation, Wnt signaling pathway and Dishevelled.
His most cited work include:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. (3614 citations)
- Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial (1436 citations)
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer (1030 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Oncology, Lung cancer, Cancer research and Surgery. His Internal medicine research focuses on subjects like Gastroenterology, which are linked to Hazard ratio. In his research on the topic of Oncology, Carcinoma is strongly related with Lung.
He has included themes like Cancer, Adenocarcinoma and Immunotherapy in his Lung cancer study. His Cancer research study integrates concerns from other disciplines, such as Carcinogenesis and Wnt signaling pathway. Julien Mazieres combines subjects such as Trametinib and Dabrafenib with his study of non-small cell lung cancer.
He most often published in these fields:
- Internal medicine (62.78%)
- Oncology (54.19%)
- Lung cancer (36.78%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (62.78%)
- Oncology (54.19%)
- Lung cancer (36.78%)
In recent papers he was focusing on the following fields of study:
Julien Mazieres focuses on Internal medicine, Oncology, Lung cancer, Cancer research and non-small cell lung cancer. His research in Oncology intersects with topics in KRAS, Clinical trial, Phases of clinical research and Durvalumab. His research integrates issues of Cancer, Targeted therapy, Immunotherapy and Retrospective cohort study in his study of Lung cancer.
He studied Cancer research and Tyrosine kinase that intersect with Adenocarcinoma. His non-small cell lung cancer research includes themes of Antibody, Trametinib and Dabrafenib. In his study, which falls under the umbrella issue of Nivolumab, Docetaxel is strongly linked to Gastroenterology.
Between 2018 and 2021, his most popular works were:
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. (181 citations)
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry (178 citations)
- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial (140 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Internal medicine, Oncology, Lung cancer, Immunotherapy and Nivolumab. His research on Internal medicine frequently links to adjacent areas such as Gastroenterology. His Gastroenterology research focuses on Docetaxel and how it connects with Bevacizumab and Pseudoprogression.
His Oncology research is multidisciplinary, incorporating elements of Progressive disease, Clinical trial, Targeted therapy, Clone and Adenocarcinoma. His Lung cancer research is multidisciplinary, relying on both Cancer, Adverse effect and Cohort. His study looks at the intersection of Nivolumab and topics like Retrospective cohort study with Thyroid function tests, Levothyroxine, Thyroid, Thyroiditis and Incidence.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
